Yosef Yarden, Ph.D.
Affiliations: | Weizmann Institute of Science, Rehovot, Israel |
Area:
Cell Biology, OncologyGoogle:
"Yosef Yarden"Parents
Sign in to add mentor| Joseph Schlessinger | grad student | (Neurotree) | |
| Robert A. Weinberg | post-doc |
Children
Sign in to add trainee| Ami Citri | grad student | Weizmann Institute (Neurotree) | |
| Sima Lev | grad student | Weizmann Institute | |
| Gil Levkowitz | grad student | Weizmann Institute | |
| Elior Peles | grad student | Weizmann Institute | |
| Sima Lev | grad student | 1989-1994 | Weizmann Institute |
| Yaara Zwang | grad student | 2009 | Weizmann Institute |
| Hadas Cohen-Dvashi | grad student | 2011 | Weizmann Institute |
| Fresia G. Pareja Zea | grad student | 2011 | Weizmann Institute |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Marrocco I, Yarden Y. (2023) Resistance of Lung Cancer to EGFR-Specific Kinase Inhibitors: Activation of Bypass Pathways and Endogenous Mutators. Cancers. 15 |
| Marrocco I, Giri S, Simoni-Nieves A, et al. (2023) L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab. Cell Reports. Medicine. 101142 |
| Hedegger K, Blutke A, Hommel T, et al. (2023) Trapping all ERBB ligands decreases pancreatic lesions in a murine model of pancreatic ductal adenocarcinoma. Molecular Oncology |
| Nataraj NB, Noronha A, Lee JS, et al. (2022) Nucleoporin-93 reveals a common feature of aggressive breast cancers: robust nucleocytoplasmic transport of transcription factors. Cell Reports. 38: 110418 |
| Gaviraghi M, Rabellino A, Andolfo A, et al. (2021) Author Correction: Direct stimulation of ERBB2 highlights a novel cytostatic signaling pathway driven by the receptor Thr phosphorylation. Scientific Reports. 11: 18202 |
| Uribe ML, Marrocco I, Yarden Y. (2021) EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance. Cancers. 13 |
| Uribe ML, Marrocco I, Yarden Y. (2021) EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance. Cancers. 13 |
| Uribe ML, Dahlhoff M, Batra RN, et al. (2021) TSHZ2 is an EGF-regulated tumor suppressor that binds to the cytokinesis regulator PRC1 and inhibits metastasis. Science Signaling. 14 |
| Gaviraghi M, Rabellino A, Andolfo A, et al. (2020) Direct stimulation of ERBB2 highlights a novel cytostatic signaling pathway driven by the receptor Thr phosphorylation. Scientific Reports. 10: 16906 |
| Shenoy A, Belugali Nataraj N, Perry G, et al. (2020) Proteomic patterns associated with response to breast cancer neoadjuvant treatment. Molecular Systems Biology. 16: e9443 |